Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

04 Jun 2025 bởi

The addition of elebsiran, an investigational small interfering ribonucleic acid (siRNA), to pegylated interferon (PEG-IFN) alfa led to a higher rate of hepatitis B surface antigen (HBsAg) loss in patients with chronic HB virus (HBV) infection compared with PEG-IFN alfa alone, according to the ENSURE study presented at EASL 2025.

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

04 Jun 2025

WAYFINDER updates boost tezepelumab role in OCS-dependent severe asthma

03 Jun 2025 bởi

Updated results from the open-label, phase IIIb WAYFINDER study continue to support the oral corticosteroid (OCS)-sparing efficacy of tezepelumab in the treatment of patients with OCS-dependent severe asthma.

WAYFINDER updates boost tezepelumab role in OCS-dependent severe asthma

03 Jun 2025

No link between nicotinamide exposure and MACE

03 Jun 2025

Adults who are exposed to nicotinamide do not appear to be at increased risk of major cardiovascular events (MACE), according to a large retrospective cohort study.

No link between nicotinamide exposure and MACE

03 Jun 2025

Modified minocycline hydrochloride formulation works against papulopustular rosacea

02 Jun 2025

In the treatment of moderate-to-severe papulopustular rosacea (PPR), the low-dose modified formulation of minocycline hydrochloride, DFD-29, appears to have superior efficacy compared with both doxycycline and placebo, according to data from the phase III MVOR-1 and MVOR-2 studies.

Modified minocycline hydrochloride formulation works against papulopustular rosacea

02 Jun 2025

Add-on zilebesiran helps lower BP in uncontrolled hypertension

01 Jun 2025 bởi

The addition of a single subcutaneous dose of zilebesiran to background therapies appears to provide blood pressure (BP)-lowering benefit in patients with uncontrolled hypertension, according to the phase II KARDIA-2 study.

Add-on zilebesiran helps lower BP in uncontrolled hypertension

01 Jun 2025

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

31 May 2025 bởi

Cytisinicline’s efficacy and tolerability for smoking cessation has been validated in another large phase III trial conducted in the US, with both the 6- and 12-week treatments yielding positive benefits persisting through 24 weeks.

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

31 May 2025

Adult-onset Still’s disease outcomes better with frontline biological vs csDMARD therapy

30 May 2025

In the first-line treatment of patients with adult-onset Still’s disease (AOSD), biological disease-modifying antirheumatic drug (DMARD) therapy is associated with increased likelihood of achieving sustained, event-free remission in addition to fewer complications compared with conventional synthetic (cs) DMARDs, according to a study from Germany.

Adult-onset Still’s disease outcomes better with frontline biological vs csDMARD therapy

30 May 2025

Even low-risk diabetes patients obtain renal, mortality benefits with SGLT2 inhibitors

30 May 2025 bởi

Sodium-glucose cotransporter-2 (SGLT2) inhibitors help reduce the risk of lung function decline and mortality in a low-risk population of patients with type 2 diabetes (T2D) who have normal or low BMI, as shown in a single-centre retrospective study from Korea.

Even low-risk diabetes patients obtain renal, mortality benefits with SGLT2 inhibitors

30 May 2025

Aspirin offers no protection against cardiac events in asymptomatic coronary stenosis

30 May 2025

Asymptomatic individuals with incidentally diagnosed coronary artery stenosis may forego the use of aspirin, with a recent study suggesting that it does not provide any significant benefit for the prevention of composite events and bleeding.

Aspirin offers no protection against cardiac events in asymptomatic coronary stenosis

30 May 2025

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

30 May 2025 bởi

Patients with extensive-stage small cell lung cancer (ES-SCLC) derive real-world clinical benefits from first-line treatment with atezolizumab combined with carboplatin and etoposide (CP/ET), reports a recent study.

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

30 May 2025

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

WAYFINDER updates boost tezepelumab role in OCS-dependent severe asthma

WAYFINDER updates boost tezepelumab role in OCS-dependent severe asthma

No link between nicotinamide exposure and MACE

No link between nicotinamide exposure and MACE

Modified minocycline hydrochloride formulation works against papulopustular rosacea

Modified minocycline hydrochloride formulation works against papulopustular rosacea

Add-on zilebesiran helps lower BP in uncontrolled hypertension

Add-on zilebesiran helps lower BP in uncontrolled hypertension

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

Adult-onset Still’s disease outcomes better with frontline biological vs csDMARD therapy

Adult-onset Still’s disease outcomes better with frontline biological vs csDMARD therapy

Even low-risk diabetes patients obtain renal, mortality benefits with SGLT2 inhibitors

Even low-risk diabetes patients obtain renal, mortality benefits with SGLT2 inhibitors

Aspirin offers no protection against cardiac events in asymptomatic coronary stenosis

Aspirin offers no protection against cardiac events in asymptomatic coronary stenosis

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC